DrugPatentWatch Database Preview

Details for Patent: 8,906,851

Which drugs does patent 8,906,851 protect, and when does it expire?

Patent 8,906,851 protects BYDUREON, BYDUREON PEN, BYDUREON BCISE, and FARXIGA, and is included in three NDAs.

This patent has twenty-nine patent family members in twenty countries.

Summary for Patent: 8,906,851

Title:	Method for treating diabetes
Abstract:	Methods for reducing body weight, altering body composition, treating diabetes, reducing HbA.sub.1c and reducing average daily blood glucose by the use of exendins, exendin agonists or exendin analog agonists are provided.
Inventor(s):	Fineman; Mark (San Diego, CA), MacConell; Leigh (San Diego, CA), Taylor; Kristin (San Diego, CA)
Assignee:	Amylin Pharmaceuticals, LLC (San Diego, CA) AstraZeneca Pharmaceuticals LP (Wilmington, DE)
Application Number:	13/708,474
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 8,906,851

Glossary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Astrazeneca Ab	BYDUREON	exenatide synthetic	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	022200-001	Jan 27, 2012		RX	Yes	Yes	➤ Sign Up	➤ Sign Up				AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS	➤ Sign Up
Astrazeneca Ab	BYDUREON PEN	exenatide synthetic	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	022200-002	Feb 28, 2014		RX	Yes	Yes	➤ Sign Up	➤ Sign Up				AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS	➤ Sign Up
Astrazeneca Ab	BYDUREON BCISE	exenatide	SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	209210-001	Oct 20, 2017		RX	Yes	Yes	➤ Sign Up	➤ Sign Up				AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS	➤ Sign Up
Astrazeneca Ab	FARXIGA	dapagliflozin	TABLET;ORAL	202293-001	Jan 8, 2014		RX	Yes	No	➤ Sign Up	➤ Sign Up				TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted

Non-Orange Book US Patents Family Members for Patent 8,906,851

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Patent No.	Title	Estimated Patent Expiration
9,884,092	Methods for treating diabetes and reducing body weight	➤ Sign Up
8,329,648	Methods for treating diabetes and reducing body weight	➤ Sign Up
8,389,472	Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease	➤ Sign Up
Patent No.	Title	Estimated Patent Expiration

International Family Members for US Patent 8,906,851

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Slovenia	1971362	➤ Sign Up
Singapore	184730	➤ Sign Up
Russian Federation	2421237	➤ Sign Up
Russian Federation	2008110504	➤ Sign Up
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration

Summary for Patent: 8,906,851

For more information try a trial or see the plans and pricing